Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
Looking at some recent stock price activity for Array BioPharma Inc. (NASDAQ:ARRY), we have spotted shares trading near the $10.92 level. Looking at some popular historical levels, we note that the 52-week high is presently $12.56, and the 52-week low is currently $6.96.